With valuations stretched on popular benchmarks and volatility picking up, many investors are asking whether their portfolios are built on hype or on substance. Elevated measures such as the Shiller CAPE Ratio and the Buffett indicator point to a market where quality and resilience matter more than ever. This article looks at three stocks from our Quality Stocks screener that are closely exposed to the current market backdrop, focusing on balance sheet strength, earnings consistency, and risk controls rather than speculation. By the end, you will have three concrete ideas to research further when thinking about quality in a pricey market.

TransMedics Group (TMDX)

Overview: TransMedics Group is a medical technology company that develops and operates the Organ Care System, a portable platform that keeps donor hearts, lungs and livers functioning outside the body so more organs can be transplanted safely. Alongside the hardware, it runs a national program that handles retrieval, logistics and transport, aiming to make transplants more reliable for hospitals and patients.

Operations: TransMedics generates about US$635.9 million from surgical and medical equipment, with roughly US$613.1 million of revenue coming from the United States and US$18.3 million from other countries.

Market Cap: US$2.3b

TransMedics Group stands out in a pricey market because its core transplant platform addresses a real medical need and is backed by strong recent execution, including record revenues and raised 2026 revenue guidance of US$727 to US$757 million. The stock trades on a P/E that is well below many medical equipment peers while still showing high profitability, with a 27% net margin and high quality earnings. This gives investors a margin of safety if volatility persists. On the other hand, there is meaningful reliance on debt, pressure on margins as the company invests heavily in trials and logistics, and regulatory or competitive risks around organ preservation technologies. For investors who want quality exposure rather than hype, those trade offs may be worth a closer look.

TransMedics Group’s record revenues and raised 2026 guidance suggest the story is still unfolding, but the real question is how that growth lines up against its balance sheet and earnings quality. Get the full picture in the analysis report for TransMedics Group

Privia Health Group (PRVA)

Overview: Privia Health Group is a physician enablement company that partners with doctors, health systems, and health plans to handle back office tasks, provide data and population health tools, and align incentives so clinicians can focus more on patient care and value based contracts. Its platform brings independent practices under a single medical group structure, giving them greater negotiating power and support while still allowing them to run their own offices.

Operations: Privia Health Group generates about US$2.25b in revenue from Healthcare Facilities & Services, all from the United States.

Market Cap: US$3.24b

Privia Health Group offers investors a way to tap into the shift toward value based care, with earnings growth that has outpaced both the US market and the Healthcare sector and analysts expecting a solid earnings growth runway. The business leans on recurring fees from physician practices and accountable care arrangements, and recent moves like the New Jersey expansion show management is still finding new ways to scale the model. At the same time, thin net margins, modest returns on equity and reliance on external borrowing mean execution needs to stay tight, especially as competition and regulation evolve. The tension between strong growth drivers and these structural challenges is what makes Privia worth a closer look for quality focused investors.

Privia Health Group’s earnings growth story and push into value based care look powerful, but the real signal sits in the analyst forecasts for Privia Health Group that could reveal where the pressure points start to show

Savaria (TSX:SIS)

Overview: Savaria is a Canadian company that designs and supplies accessibility and patient handling equipment, from home and commercial elevators and stairlifts to ceiling lifts, slings and medical beds. It helps elderly and physically challenged people live more independently at home and in care settings across Canada, the United States, Europe and other regions.

Operations: Savaria generates about CA$723.7 million from its Accessibility segment, including adapted vehicles, and CA$205.1 million from Patient Care products and solutions.

Market Cap: CA$2.1b

Savaria operates at the intersection of aging demographics and healthcare accessibility, with earnings up 60% over the past year, solid revenue growth, and a monthly dividend policy that currently equates to a 1.89% yield. The company is executing on margin improvement but relies heavily on external borrowing and faces risks from subsidy changes, slower product ramp ups and softer regions such as parts of Europe. Combined with recent insider selling and compensation questions, this is a quality-focused stock that still requires careful scrutiny of balance sheet strength, cash generation and governance before deciding how it fits into a long-term portfolio built for resilience.

Savaria’s earnings surge and monthly dividend point to a stronger story than the headline yield suggests, but the balance sheet and governance questions deserve a closer look, starting with the analysis report for Savaria

The three quality stocks in this article are a starting point, and the full Quality Stocks screener surfaces 46 more companies with similarly compelling financial profiles and business narratives that might fit a higher bar for resilience. Use Simply Wall St to identify, analyze, and filter for the exact catalysts, balance sheet strength, earnings consistency, and risk factors that matter most so you can focus on the highest conviction ideas in minutes.

Take Control of Your Investment Journey

If Privia Health Group or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly?

Fresh ideas do not stay under the radar for long. As momentum builds and potential breakouts form, the best entry points can be caught or missed quickly, so consider acting promptly if they fit your strategy.

• Spot cash rich companies before momentum catches on by scanning a curated list of solid balance sheet and fundamentals (47 results) that keeps financial resilience front and center.
• Track fast moving digital finance trends with a focused set of 19 cryptocurrency and blockchain stocks that may benefit if blockchain adoption keeps building.
• Review hand picked 29 robotics and automation stocks positioned around automation, manufacturing efficiency, and potential long term productivity improvements.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.